193 related articles for article (PubMed ID: 11849387)
1. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis.
Bos H; Henning RH; De Boer E; Tiebosch AT; De Jong PE; De Zeeuw D; Navis G
Kidney Int; 2002 Feb; 61(2):473-80. PubMed ID: 11849387
[TBL] [Abstract][Full Text] [Related]
2. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.
Wapstra FH; Van Goor H; Navis G; De Jong PE; De Zeeuw D
Clin Sci (Lond); 1996 May; 90(5):393-401. PubMed ID: 8665777
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
Windt WA; van Dokkum RP; Kluppel CA; Jeronimus-Stratingh CM; Hut F; de Zeeuw D; Henning RH
Eur J Pharmacol; 2008 Feb; 580(1-2):231-40. PubMed ID: 18036585
[TBL] [Abstract][Full Text] [Related]
4. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis.
Wapstra FH; Navis G; DE Jong PE; DE Zeeuw D
J Am Soc Nephrol; 2000 Mar; 11(3):490-496. PubMed ID: 10703672
[TBL] [Abstract][Full Text] [Related]
5. Inter-individual differences in anti-proteinuric response to ACEi in established adriamycin nephrotic rats are predicted by pretreatment renal damage.
Kramer AB; Laverman GD; van Goor H; Navis G
J Pathol; 2003 Sep; 201(1):160-7. PubMed ID: 12950029
[TBL] [Abstract][Full Text] [Related]
6. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
[TBL] [Abstract][Full Text] [Related]
7. Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis.
Wapstra FH; van Goor H; de Jong PE; Navis G; de Zeeuw D
J Pharmacol Toxicol Methods; 1999; 41(2-3):69-73. PubMed ID: 10598677
[TBL] [Abstract][Full Text] [Related]
8. Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?
Bos H; Henning RH; De Jong PE; De Zeeuw D; Navis G
Nephrol Dial Transplant; 2002 May; 17(5):793-7. PubMed ID: 11981065
[TBL] [Abstract][Full Text] [Related]
9. Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.
Haas M; de Boer E; de Jong PE; Moolenaar F; Meijer DK; de Zeeuw D
Clin Sci (Lond); 2003 Jul; 105(1):51-7. PubMed ID: 12636872
[TBL] [Abstract][Full Text] [Related]
10. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.
Bos H; Laverman GD; Henning RH; Tiebosch AT; de Jong PE; de Zeeuw D; Navis G
J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):106-12. PubMed ID: 12806593
[TBL] [Abstract][Full Text] [Related]
11. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
12. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
Kramer AB; van der Meulen EF; Hamming I; van Goor H; Navis G
Kidney Int; 2007 Mar; 71(5):417-24. PubMed ID: 17213874
[TBL] [Abstract][Full Text] [Related]
13. ACE inhibition preserves heparan sulfate proteoglycans in the glomerular basement membrane of rats with established adriamycin nephropathy.
Wapstra FH; Navis GJ; van Goor H; van den Born J; Berden JH; de Jong PE; de Zeeuw D
Exp Nephrol; 2001; 9(1):21-7. PubMed ID: 11053977
[TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin II antagonism on the regression of kidney disease in the rat.
Remuzzi A; Gagliardini E; Donadoni C; Fassi A; Sangalli F; Lepre MS; Remuzzi G; Benigni A
Kidney Int; 2002 Sep; 62(3):885-94. PubMed ID: 12164870
[TBL] [Abstract][Full Text] [Related]
15. Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable.
de Boer E; Navis G; Wapstra FH; de Jong PE; de Zeeuw D
Kidney Int Suppl; 1999 Jul; 71():S42-6. PubMed ID: 10412735
[TBL] [Abstract][Full Text] [Related]
16. Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors.
van der Wouden EA; Henning RH; Deelman LE; Roks AJ; Boomsma F; de Zeeuw D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):96-101. PubMed ID: 16470489
[TBL] [Abstract][Full Text] [Related]
17. Dual renin-angiotensin system blockade at optimal doses for proteinuria.
Laverman GD; Navis G; Henning RH; de Jong PE; de Zeeuw D
Kidney Int; 2002 Sep; 62(3):1020-5. PubMed ID: 12164886
[TBL] [Abstract][Full Text] [Related]
18. Sodium intake modifies the negative prognostic value of renal damage prior to treatment with ACE inhibitors on proteinuria induced by adriamycin.
Kramer AB; Bos H; van Goor H; Navis GJ
Nephron Physiol; 2006; 103(1):p43-52. PubMed ID: 16352916
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.
Laverman GD; Van Goor H; Henning RH; De Jong PE; De Zeeuw D; Navis G
Kidney Int; 2003 Jan; 63(1):64-71. PubMed ID: 12472769
[TBL] [Abstract][Full Text] [Related]
20. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
